MOPP/ABV/CAD chemotherapy with and without recombinant human granulocyte-macrophage colony stimulating factor in untreated, unfavorable prognosis Hodgkin's disease

A. Riccardi, P. Gobbi, M. Danova, M. Giordano, C. Pieresca, D. Bertoloni, S. Brugnatelli, E. Ascari

Research output: Contribution to journalArticle

Abstract

Seventeen consecutive patients with previously untreated poor prognosis Hodgkin's disease (clinical stage II and III with systemic symptoms, and stage IV) received 6 courses of aggressive chemotherapy, with (9 patients) and without (8 patients) the addition of recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF). Chemotherapy (MOPP/ABV/CAD regimen) included full doses of nitrogen mustard, lomustine (CCNU), vindesine, melphalan, prednisone, epidoxorubicin, vincristine, procarbazine, vinblastine and bleomycin, and was administered between days 1 and 15 of each course. Course were planned for 28-day intervals. rhGM-CSF was given at a dose of 5 μ/kg/day subcutaneously from day 16 to 26 of each course. With cytopenia (i.e. white blood cell, WBC, count <3.0 x 109/L and/or platelet count <100 x 109/L) delaying courses was preferred to administering reduced drug dosages. Substantial delays (ranging from 7 to 28 days) in delivering cytostatics were necessary between 70% of courses. The cumulative mean number of days for which the courses had to be delayed before completing the 6 MOPP/ABV/CAD courses was 57. The percentage of planned doses of cytotoxic drugs (nitrogen mustard, melphalan, epidoxorubicin, procarbazine) actually administered was 92%. Causes of treatment delay were represented by leucopenia in 82% and by leuco-thrombocytopenia in 23% of the courses. The WBC nadir was constantly encountered at day 20-21 following completion of courses, and slightly worsened with subsequent courses. The decrease in platelet values was milder than that in WBC counts. There were no differences in any of the above parameters between patients treated with MOPP/ABV/CAD alone or followed by rhGM-CSF. Side effects of rhGM-CSF were frequent but not severe (myalgias, 48% of the cycles; low-grade fever, 30% of the cycles; epigastralgias, 15% of the cycles). Of the 17 patients, 15 achieved complete remission and one partial remission. This study indicates that aggressive chemotherapy is effective in patients with untreated, advanced stage Hodgkin's disease, not with standing substantial delays in drug timing due to leuco- or leuco-thrombocytopenia. rhGM-CSF, administered in the intervals between courses at a dose of 5 μg/kg/day, was not effective in reducing leucopenia or in improving the drug scheduling.

Original languageEnglish
Pages (from-to)44-48
Number of pages5
JournalHaematologica
Volume78
Issue number1
Publication statusPublished - 1993

Keywords

  • Hodgkin's disease
  • leucopenia
  • MOPP/ABV/CAD chemotherapy
  • recombinant human granulocyte-macrophage colony stimulating factor

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'MOPP/ABV/CAD chemotherapy with and without recombinant human granulocyte-macrophage colony stimulating factor in untreated, unfavorable prognosis Hodgkin's disease'. Together they form a unique fingerprint.

  • Cite this